Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:48:27.803Z.
Calculation as of: 2026-10-06T18:48:27.803Z.
Quote observation: 2026-10-06T18:38:47.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4f0d9278b3abed9c67286a4c42ed3cbe71797fc66aa4bad88dc285e5ed2b1466
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$67.01M
EBITDA Yield
433.74%
TTM Avg
3466.62%
3Y Avg
3466.62%
5Y Avg
3466.62%
Market Cap
$68.08M
EBITDA Yield
0.39%
TTM Avg
3.41%
3Y Avg
4.41%
5Y Avg
3.27%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| XBiotech Inc. (XBIT) | $66.16M | N/A | N/A | N/A | N/A |
| iBio, Inc. (IBIO)vs › | $66.56M | N/A | N/A | N/A | N/A |
| Cingulate Inc. (CING)vs › | $67.01M | 433.74% | 3466.62% | 3466.62% | 3466.62% |
| Gossamer Bio, Inc. (GOSS)vs › | $64.53M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $68.08M | 0.39% | 3.41% | 4.41% | 3.27% |
| RenovoRx, Inc. (RNXT)vs › | $63.97M | N/A | N/A | N/A | N/A |
| Tiziana Life Sciences Ltd (TLSA)vs › | $68.40M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.60M | N/A | N/A | N/A | N/A |
| Alps Group Inc (ALPS)vs › | $63.58M | N/A | N/A | N/A | N/A |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.47M | N/A | 8.85% | 8.85% | 8.85% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
